Liptzin Deborah R, Watson Alan M, Murphy Elissa, Kroehl Miranda E, Dishop Megan K, Galambos Csaba, Evans Christopher M, Schwarz Marvin I, Deterding Robin R, Schwartz David A
Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Pediatr Pulmonol. 2015 Dec;50(12):1270-6. doi: 10.1002/ppul.23180. Epub 2015 Apr 7.
Mutations in Surfactant Protein C (SFTPC) can lead to fibrotic interstitial lung disease (ILD) with variable phenotypes, especially in children. The sources of phenotype variability are incompletely understood. A common MUC5B promoter variant rs35705950 is associated with adult Idiopathic Pulmonary Fibrosis (IPF). We examined whether MUC5B is similarly linked to ILD secondary to SFTPC mutations.
MUC5B concentration in bronchoalveolar lavage fluid (BALF) was measured in six pediatric patients with SFTPC mutations and diseased controls. Immunohistochemical localization of MUC5B was studied in fixed lung tissues in patients with SFTPC mutations, ABCA3 mutations, and controls. Genotyping for the MUC5B promoter variant rs35705950 was attempted in all samples.
MUC5B glycoprotein was increased in BALF of patients with SFTPC mutations compared to diseased controls (P = 0.04). MUC5B was unexpectedly present in cells morphologically consistent with alveolar epithelial type II cells in patients with SFTPC mutations in the BRICHOS domain. Genotyping for the MUC5B promoter variant was successful in 18/27 patients, and there was no significant relationship between the MUC5B promoter variant and the BALF or MUC5B localization.
MUC5B may play a role in the development of fibrosis in patients with SFTPC mutations, especially in patients with BRICHOS mutations. Understanding the role of MUC5B in adult and pediatric lung diseases may lead to a better understanding of the etiology of fibrotic lung disease as well as development of novel therapies.
表面活性蛋白C(SFTPC)突变可导致具有不同表型的纤维化间质性肺疾病(ILD),尤其是在儿童中。表型变异的来源尚不完全清楚。常见的MUC5B启动子变体rs35705950与成人特发性肺纤维化(IPF)相关。我们研究了MUC5B是否同样与SFTPC突变继发的ILD有关。
测量了6例患有SFTPC突变的儿科患者和患病对照的支气管肺泡灌洗液(BALF)中的MUC5B浓度。在患有SFTPC突变、ABCA3突变的患者以及对照的固定肺组织中研究了MUC5B的免疫组织化学定位。尝试对所有样本进行MUC5B启动子变体rs35705950的基因分型。
与患病对照相比,SFTPC突变患者的BALF中MUC5B糖蛋白增加(P = 0.04)。在BRICHOS结构域有SFTPC突变的患者中,MUC5B意外地存在于形态上与II型肺泡上皮细胞一致的细胞中。18/27例患者成功进行了MUC5B启动子变体的基因分型,且MUC5B启动子变体与BALF或MUC5B定位之间无显著关系。
MUC5B可能在SFTPC突变患者的纤维化发展中起作用,尤其是在有BRICHOS突变的患者中。了解MUC5B在成人和儿童肺部疾病中的作用可能有助于更好地理解纤维化肺病的病因以及开发新的治疗方法。